Verastem Oncology (Nasdaq: VSTM) has priced an underwritten public offering of common stock and pre-funded warrants expected to raise approximately $250 million in gross proceeds, according to a press release from the company.

The offering consists of 30,937,500 shares of common stock priced at $8.00 per share. Certain investors will receive pre-funded warrants to purchase up to 312,503 shares at $7.9999 per warrant, reflecting the per-share price less a $0.0001 exercise price. All securities are being sold by Verastem Oncology.

The offering is expected to close on or about October 15, 2026, subject to customary closing conditions. Gross proceeds do not account for underwriting discounts, commissions, and other offering expenses.

Jefferies, Guggenheim Securities, and Cantor are serving as joint book-running managers. B. Riley Securities is acting as lead manager.

Verastem Oncology said it intends to use net proceeds to fund continued clinical development of its product candidates, including the VS-7375 program, as well as for working capital and general corporate purposes.

The offering is registered under a shelf registration statement on Form S-3 that the Securities and Exchange Commission declared effective on August 15, 2025.